Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and prevents oxidative stress in uremic rats

Hypertension

Volumn 52, Issue 2, 2008, Pages 295-300

  Michea, Luis ^a   Villagrán, Andrea ^b   Urzúa, Alvaro ^b   Kuntsmann, Sonia ^b,c   Venegas, Patricio ^a,c   Carrasco, Loreto ^a,b   Gonzalez, Magdalena ^a   Marusic, Elisa T ^b  

^a UNIVERSITY OF CHILE   (Chile)

^b UNIVERSIDAD DE LOS ANDES   (Chile)

^c CLÍNICA LAS CONDES   (Chile)

Author keywords

Aldosterone; Cardiac hypertrophy; Hydroxysteroid dehydrogenase type 2; Mineralocorticoid receptor; Oxidative stress; SGK1

Indexed keywords

ALDOSTERONE; ALDOSTERONE SYNTHASE; BRAIN NATRIURETIC PEPTIDE; GLUCOCORTICOID RECEPTOR; HYDROXYSTEROID DEHYDROGENASE; HYDROXYSTEROID DEHYDROGENASE TYPE 2; MESSENGER RNA; MINERALOCORTICOID RECEPTOR; PROTEIN P47; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; SERUM AND GLUCOCORTICOID REGULATED KINASE 1; SPIRONOLACTONE; SUPEROXIDE; UNCLASSIFIED DRUG; ALDOSTERONE ANTAGONIST; BIOLOGICAL MARKER; IMMEDIATE EARLY PROTEIN; PROTEIN SERINE THREONINE KINASE; SERUM GLUCOCORTICOID REGULATED KINASE; SERUM-GLUCOCORTICOID REGULATED KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; ECHOCARDIOGRAPHY; GENE EXPRESSION; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE CELL; HEART RIGHT VENTRICLE; HEART STRESS; HEART VENTRICLE HYPERTROPHY; MALE; NEPHRECTOMY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RECEPTOR BLOCKING; SYSTOLIC BLOOD PRESSURE; UREMIA; ANALYSIS OF VARIANCE; ANIMAL; CARDIOMEGALY; DISEASE MODEL; DRUG ANTAGONISM; GENETICS; METABOLISM; PATHOPHYSIOLOGY; PROBABILITY; RANDOMIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPRAGUE DAWLEY RAT; URINALYSIS; WESTERN BLOTTING;

ALDOSTERONE ANTAGONISTS; ANALYSIS OF VARIANCE; ANIMALS; BIOLOGICAL MARKERS; BLOTTING, WESTERN; CARDIOMEGALY; DISEASE MODELS, ANIMAL; IMMEDIATE-EARLY PROTEINS; MALE; NEPHRECTOMY; OXIDATIVE STRESS; PROBABILITY; PROTEIN-SERINE-THREONINE KINASES; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, MINERALOCORTICOID; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SPIRONOLACTONE; UREMIA; URINALYSIS;

EID: 49849099862     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.107.109645     Document Type: Article

References (41)

1. McClellan WM. Epidemiology and risk factors for chronic kidney disease. Med Clin North Am. 2005;89:419-445.
2. Amann K, Neususs R, Ritz E, Irzyniec T, Wiest G, Mall G. Changes of vascular architecture independent of blood pressure in experimental uremia. Am J Hypertens. 1995;8:409-417.
3. Mall G, Rambausek M, Neumeister A, Kollmar S, Vetterlein F, Ritz E. Myocardial interstitial fibrosis in experimental uremia-implications for cardiac compliance. Kidney Int. 1988;33:804-811.
4. Rambausek M, Ritz E, Mall G, Mehls O, Katus H. Myocardial hypertrophy in rats with renal insufficiency. Kidney Int. 1985;28:775-782.
5. Mak RH, Chang SL, Draksharapu A, Pak YK. Gene expression in uremic left ventricular hypertrophy: effects of hypertension and anemia. Exp Mol Med. 2004;36:251-258.
6. Rocha R, Funder JW. The pathophysiology of aldosterone in the cardiovascular system. Ann N Y Acad Sci. 2002;970:89-100.
7. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Ferez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709-717.
8. Kobayashi N, Yoshida K, Nakano S, Ohno T, Honda T, Tsubokou Y, Matsuoka H. Cardioprotective mechanisms of eplerenone on cardiac performance and remodeling in failing rat hearts. Hypertension. 2006;47: 671-679.
9. Lombes M, Alfaidy N, Eugene E, Lessana A, Farman N, Bonvalet JP. Prerequisite for cardiac aldosterone action. Mineralocorticoid receptor and 11 beta-hydroxysteroid dehydrogenase in the human heart. Circulation. 1995;92:175-182.
10. Alzamora R, Michea L, Marusic ET. Role of 11 beta-hydroxysteroid dehydrogenase in nongenomic aldosterone effects in human arteries. Hypertension. 2000;35:1099-1104.
11. Le Menuet D, Isnard R, Bichara M, Viengchareun S, Muffat-Joly M, Walker F, Zennaro MC, Lombes M. Alteration of cardiac and renal functions in transgenic mice overexpressing human mineralocorticoid receptor. J Biol Chem. 2001;276:38911-38920.
12. Takeda Y. Pathophysiological roles of vascular 11beta-hydroxysteroid dehydrogenase and aldosterone. J Steroid Biochem Mol Biol. 2003;85: 443-447.
13. Young MJ, Moussa L, Dilley R, Funder JW. Early inflammatory responses in experimental cardiac hypertrophy and fibrosis: effects of 11 beta-hydroxysteroid dehydrogenase inactivation. Endocrinology. 2003; 144:1121-1125.
14. Silvestre JS, Robert V, Heymes C, Aupetit-Faisant B, Mouas C, Moalic JM, Swynghedauw B, Delcayre C. Myocardial production of aldosterone and corticosterone in the rat. Physiological regulation. J Biol Chem. 1998;273:4883-4891.
15. Gomez-Sanchez EP, Ahmad N, Romero DG, Gomez-Sanchez CE. Origin of aldosterone in the rat heart. Endocrinology. 2004;145:4796-4802.
16. Ye P, Kenyon CJ, MacKenzie SM, Jong AS, Miller C, Gray GA, Wallace A, Ryding AS, Mullins JJ, McBride MW, Graham D, Fraser R, Connell JM, Davies E. The aldosterone synthase (CYP11B2) and 11betahydroxylase (CYP11B1) genes are not expressed in the rat heart Endocrinology. 2005;146:5287-5293.
17. Lister K, Autelitano DJ, Jenkins A, Hannan RD, Sheppard KE. Cross talk between corticosteroids and alpha-adrenergic signalling augments cardiomyocyte hypertrophy: a possible role for SGK1. Cardiovasc Res. 2006; 70:555-565.
18. Aoyama T, Matsui T, Novikov M, Park J, Hemmings B, Rosenzweig A. Serum and glucocorticoid-responsive kinase-1 regulates cardiomyocyte survival and hypertrophic response. Circulation. 2005;111:1652-1659.
19. Kobayashi T, Cohen P. Activation of serum- and glucocorticoid-regulated protein kinase by agonists that activate phosphatidylinositide 3-kinase is mediated by 3-phosphoinositide-dependent protein kinase-1 (PDK1) and PDK2. Biochem J. 1999;339:319-328.
20. Park J, Leong ML, Buse P, Maiyar AC, Firestone GL, Hemmings BA. Serum and glucocorticoid-inducible kinase (SGK) is a target of the PI 3-kinase-stimulated signaling pathway. EMBO J. 1999;18:3024-3033.
21. Sun Y, Zhang J, Lu L, Chen SS, Quinn MT, Weber KT. Aldosterone-induced inflammation in the rat heart: role of oxidative stress. Am J Pathol. 2002;161:1773-1781.
22. Young M, Funder JW. Eplerenone, but not steroid withdrawal, reverses cardiac fibrosis in deoxycorticosterone/salt-treated rats. Endocrinology. 2004;145:3153-3157.
23. Park YM, Park MY, Sun YL, Park JB. NAD(P)H oxidase inhibitor prevents blood pressure elevation and cardiovascular hypertrophy in aldosterone-infused rats. Biochem Biophys Res Commun. 2004;313: 812-817.
24. Chai W, Garrelds IM, de Vries R, Danser AH. Cardioprotective effects of eplerenone in the rat heart: interaction with locally synthesized or blood-derived aldosterone? Hypertension. 2006;47:665-670.
25. de Simone G, Wallerson DC, Volpe M, Devereux RB. Echocardiographic measurement of left ventricular mass and volume in normotensive and hypertensive rats. Necropsy validation. Am J Hypertens. 1990;3: 688-696.
26. Gonzalez M, Lobos L, Castillo F, Galleguillos L, Lopez NC, Michea L. High-salt diet inhibits expression of angiotensin type 2 receptor in resistance arteries. Hypertension. 2005;45:853-859.
27. Michea L, Valenzuela V, Bravo I, Schuster A, Marusuic ET. Adrenal-dependent modulation of the catalytic subunit isoforms of the Na+-K+-ATPase in aorta. Am J Physiol. 1998;275:E1072-E1081.
28. Khan SA, Lee K, Minnas KM, Gonzalez DR, Raju SV, Tejani AD, Li D. Berkowitz DE, Hare JM. Neuronal nitric oxide synthase negatively regulates xanthine oxidoreductase inhibition of cardiac excitation-contraction coupling.Proc Natl Acad Sci U S A. 2004;101:15944-15948.
29. Qin W, Rudolph AE, Bond BR, Rocha R, Blomme EA, Goellner JJ, Funder JW, McMahon EG. Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure. Circ Res. 2003;93:69-76.
30. Ouvrard-Pascaud A, Jaisser F. Pathophysiological role of the mineralo-corticoid receptor in heart: analysis of conditional transgenic models. Pflugers Arch. 2003;445:477-481.
31. Tanabe A, Naruse M, Adachi C, Seki T, Yoshimoto T, Takagi S, Naruse K, Takano K. Hydralazine decreases blood pressure and endothelin-1 mRNA expression in tissues but not cardiac weight in SHR-SP/Izm rats. J Cardiovasc Pharmacol. 2000;36:S176-S178.
32. Cavallero S, Gonzalez GE, Puyo AM, Roson MI, Perez S, Morales C, Hertig CM, Gelpi RJ, Femandez BE. Atrial natriuretic peptide behaviour and myocyte hypertrophic profile in combined pressure and volume-induced cardiac hypertrophy. J Hypertens. 2007;25:1940-1950.
33. Dananberg J, Grekin RJ. Corticoid regulation of atrial natriuretic factor secretion and gene expression. Am J Physiol. 1992;263:H1377-H1381.
34. Yamamuro M, Yoshimura M, Nakayama M, Abe K, Shono M, Suzuki S, Sakamoto T, Saito Y, Nakao K, Yasue H, Ogawa H. Direct effects of aldosterone on cardiomyocytes in the presence of normal and elevated extracellular sodium. Endocrinology. 2006;147:1314-1321.
35. Vallon V, Wyatt AW, Klingel K, Huang DY, Hussain A, Berchtold S. Friedrich B, Grahammer F, Belaiba RS, Gorlach A, Wulff P, Daut J, Dalton ND, Ross J Jr, Flogel U, Schrader J, Osswald H, Kandolf R, Kuhl D, Lang F. SGK1-dependent cardiac CTGF formation and fibrosis following DOCA treatment. J Mol Med. 2006;84:396-404.
36. White PC. Aldosterone: direct effects on and production by the heart. J Clin Endocrinol Metab. 2003;88:2376-2383.
37. Funder JW. RALES, EPHESUS and redox. J Steroid Biochem Mol Biol. 2005;93:121-125.
38. Kennedy DJ, Vetteth S, Periyasamy SM, Kanj M, Fedorova L, Khouri S. Kahaleh MB, Xie Z, Malhotra D, Kolodkin NI, Lakatta EG, Fedorova OV, Bagrov AY, Shapiro JI. Central role for the cardiotonic steroid marinobufagenin in the pathogenesis of experimental uremic cardiomyopathy. Hypertension. 2006;47:488-495.
39. Gomez-Sanchez EP, Fort CM, Gomez-Sanehez CE. Intracerebroventricular infusion of RU28318 blocks aldosterone-salt hypertension. Am J Physiol. 1990;258:E482-E484.
40. Michea L, Vukusich A, Gonzalez M, Zehnder C, Marusic ET. Effect of spironolactone on K(+) homeostasis and ENaC expression in lymphocytes from chronic hemodialysis patients. Kidney Int. 2004;66: 1647-1653.
41. Morena M, Cristol JP, Senecal L, Leray-Moragues H, Krieter D, Canaud B. Oxidative stress in hemodialysis patients: is NADPH oxidase complex the culprit? Kidney Int Suppl. 2002:109-114.